Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;149(5):474-483.
doi: 10.1159/000538529. Epub 2024 Mar 30.

Age-Stratified Clinical Outcome in Patients with Known Heart Failure Who Receive Pacemaker, Resynchronization Therapy, or Defibrillator Implants

Affiliations

Age-Stratified Clinical Outcome in Patients with Known Heart Failure Who Receive Pacemaker, Resynchronization Therapy, or Defibrillator Implants

Cecilia Rorsman et al. Cardiology. 2024.

Abstract

Introduction: Patients with heart failure (HF) and bradycardia may be eligible for different types of cardiac implantable electronic devices (CIED), depending on the presence of atrioventricular conduction disease, age, and comorbidities. We aimed to assess the prognosis for these patients, after CIED implantation, stratified for the type of CIED device.

Methods: All patients with preexisting HF diagnosis who received a CIED with a right ventricular lead during the period 2005-2018 in Sweden were identified via the pacemaker registry. Data were crossmatched with the population registry and national disease registries. The outcome was 5-year risk of HF hospitalization and mortality.

Results: A total of 37,745 patients were included in the study. Comparing demographics for implantable cardioverter defibrillator versus pacemaker implants, median age was 66 years versus 83 years, 20% versus 41% were female, 64% versus 50% had ischemic heart disease, and 35% versus 67% had atrial fibrillation (all p < 0.001). Five-year mortality was highest in single-chamber pacemaker recipients (61% compared to average 40%, p < 0.001), but the proportion of cardiovascular mortality was highest for cardiac resynchronization therapy (CRT) recipients (68% vs. 63% p < 0.001). Adjusted mortality was higher for pacemaker patients in all age decile groups (ranging from <60 to >90 years old, all p < 0.001), HF hospitalization occurred in 28% (dual-chamber pacemaker) to 39% (CRT-P) of patients, and cause of death was HF in 15% (dual-chamber pacemaker) to 25% (CRT-D), all p < 0.001.

Conclusion: In this large real-world cohort of CIED-treated patients with prior HF, demography and mortality data indicate that clinicians chose devices according to the overall status of the patient. HF-related events occurred in all groups but were more common in CRT-treated patients.

Keywords: Cardiac resynchronization therapy; Heart failure; Pacemaker; Prognosis.

PubMed Disclaimer

Conflict of interest statement

R.B. has received speaker’s fees from Medtronic, Abbott, and Biotronik, has research grants from Boston Scientific, and is currently an employee of the non-profit Novo Nordisk Foundation. The other authors have no conflicts of interests.

Figures

Fig. 1.
Fig. 1.
Flowchart of included patients.
Fig. 2.
Fig. 2.
Upgrades to ICD or CRT, stratified by device type at the index implant procedure.
Fig. 3.
Fig. 3.
Kaplan-Meier curves showing age and type of device-adjusted survival for all patients. Upper left image shows all patients, and the other curves show age-stratified results within age groups according to figure legends below. Variables in the adjusted model include age, gender, prior cerebrovascular disease, chronic obstructive lung disease, diabetes, hypertension, atrial fibrillation, ischemic heart disease, chronic kidney disease, and ECG indication. Log rank p value <0.0001.
Fig. 4.
Fig. 4.
Kaplan-Meier curves for patients with bradycardia indication “AV block,” showing adjusted survival stratified by type of device implanted. Variables in the adjusted model include age, gender, prior cerebrovascular disease, chronic obstructive lung disease, diabetes, hypertension, atrial fibrillation, ischemic heart disease, and chronic kidney disease. Log rank p value <0.0001.

Similar articles

Cited by

References

    1. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. . 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427–520. - PubMed
    1. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. . 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation. 2019;140(8):e382–482. - PubMed
    1. Tolppanen H, Siirila-Waris K, Harjola VP, Marono D, Parenica J, Kreutzinger P, et al. . Ventricular conduction abnormalities as predictors of long-term survival in acute de novo and decompensated chronic heart failure. ESC Heart Fail. 2016;3(1):35–43. - PMC - PubMed
    1. Hebert K, Quevedo HC, Tamariz L, Dias A, Steen DL, Colombo RA, et al. . Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender. Ann Noninvasive Electrocardiol. 2012;17(2):113–22. - PMC - PubMed
    1. Tops LF, Schalij MJ, Bax JJ. The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. J Am Coll Cardiol. 2009;54(9):764–76. - PubMed

MeSH terms